Human Immune Monitoring

$80,978P30FY2012CANIH

Stanford University, Stanford CA

Investigators

Linked publications, trials & patents

Paper 39574895 Paper 39534431 Paper 39506045 Paper 39378093 Paper 39257774 Paper 39179931 Paper 39163262 Paper 39132489 Paper 39042439 Paper 38997156 Paper 38996463 Paper 38987048 Paper 38968138 Paper 38838737 Paper 38810650 Paper 38746193 Paper 38563850 Paper 38496616 Paper 38496500 Paper 38408498 Paper 38387457 Paper 38278150 Paper 38273211 Paper 38262408 Paper 38260330 Paper 38200310 Paper 38154193 Paper 38096469 Paper 37963187 Paper 37917579 Paper 37882771 Paper 37812494 Paper 37743567 Paper 37667254 Paper 37662553 Paper 37534980 Paper 37532139 Paper 37527449 Paper 37398193 Paper 37244414 Paper 37196642 Paper 37184546 Paper 37162847 Paper 36999999 Paper 36993756 Paper 36813894 Paper 36747642 Paper 36734849 Paper 36729432 Paper 36729074 Paper 36719070 Paper 36717409 Paper 36711732 Paper 36701540 Paper 36652552 Paper 36640300 Paper 36635501 Paper 36624348 Trial NCT05220254 Trial NCT03733210 Trial NCT03405142 Trial NCT03241940 Trial NCT03179449 Trial NCT02855086 Trial NCT02805075 Trial NCT02762266 Trial NCT02736578 Trial NCT02735356 Trial NCT02699723 Trial NCT02695628 Trial NCT02690948 Trial NCT02683824 Trial NCT02635074 Trial NCT02624518 Trial NCT02599194 Trial NCT02581787 Trial NCT02488070 Trial NCT02440308 Trial NCT02432118 Trial NCT02429804 Trial NCT02415608 Trial NCT02401347 Trial NCT02215928 Trial NCT02210858 Trial NCT02203565 Trial NCT02184533 Trial NCT02175745 Trial NCT02166983 Trial NCT02058550 Trial NCT02030405 Trial NCT02019069 Trial NCT01977677 Trial NCT01943188 Trial NCT01928030 Trial NCT01926990 Trial NCT01908166 Trial NCT01904643 Trial NCT01898403 Trial NCT01893892 Trial NCT01868503

Abstract

The Human Immune Monitoring Center (HIMC) Shared Resource provides state-of-the-art assays that measure biomarkers relevant to the immune system or specific pathogens. Examples of biomarkers that are specifically relevant to cancer include changes in lymphocyte signaling pathways, serum cytokines, and specific immune responses that target tumor cells. This resource offers Cancer Center members specialized assays that monitor the effects and efficacy of immunotherapies and vaccination strategies that are becoming increasingly important alternatives or adjuvants to conventional forms of cancer treatment. In addition, pathogens have been implicated in the etiology of many cancers, and the HIMC offers array methodologies for pathogen identification. The HIMC initiated operations in early 2007, and has attracted many faculty users in the past two years; 74% of the current users are Cancer Center members. We expect an increasing demand for our services as new projects and clinical trials in the immune modulation of cancer are developed. Major services provided by the HIMC are Luminex bead-based assays for measuring cytokines, FACS phenotyping and phosphoflow analysis for cell characterization, and the Firefly nanofluidics assay method for detecting phosphorylated proteins. Dr. Holden Maecker is the Facility Director of HIMC and an expert in cancer immunology and immune monitoring. Leadership is provided by Dr. Maecker and oversight is provided by the HIMC Advisory Committee, consisting of 10 faculty and headed by Dr. Mark Davis, who is an internationally known expert in lymphocyte recognition and immune monitoring technologies. He is also the principal inventor of the peptide-MHC tetramer technology to monitor specific T cell responses. Future goals of the HIMC are to introduce for general use the multiplex peptide-MHC tetramer technology recently developed by the Davis lab to quantitate and characterize T cell responses to tumor associated antigens and the complementary ELISPOT analysis, which quantitates T and B cell responses. The shared resource will also offer full bioinformatics consulting and data management for its users.

View original record on NIH RePORTER →